Anticoagulation Management in Atrial Fibrillation

Introduction to Anticoagulation Management

The American College of Cardiology/American Heart Association guidelines recommend against bridging anticoagulation for most atrial fibrillation patients, as it increases bleeding risk without reducing thromboembolic events, based on strong evidence from guidelines published in 2021 and 2014 [1] [2]

Patients with mechanical heart valves require bridging anticoagulation, according to the American College of Cardiology guidelines published in 2014 1
Patients with very high thromboembolic risk, such as those with recent stroke/TIA, CHA₂DS₂-VASc score ≥7, or history of perioperative stroke, may require bridging therapy 3, 4
A CHA₂DS₂-VASc score of 6 or higher represents high risk and may warrant bridging anticoagulation, especially with additional risk factors like prior stroke, according to the American College of Chest Physicians 4

The American College of Cardiology/American Heart Association guidelines recommend continuing warfarin at an adjusted dose to achieve therapeutic INR, monitoring INR more frequently (at least weekly) until stable, for most atrial fibrillation patients, based on guidelines published in 2021 2
Consider direct oral anticoagulants (DOACs) if a patient has difficulty maintaining therapeutic INR, as DOACs are now recommended over warfarin in DOAC-eligible patients with atrial fibrillation, according to the American College of Cardiology guidelines published in 2021 2

In rare cases where bridging is deemed necessary (mechanical valve or extremely high risk), start Lovenox when INR falls below 2.0, use weight-based dosing of enoxaparin (1 mg/kg twice daily), and continue until INR reaches ≥2.0, adjusting dose for renal impairment, based on guidelines published in 2021 2
For patients who require bridging, the American College of Cardiology recommends stopping warfarin 5 days before procedure and starting Lovenox when INR falls below 2.0 (typically 3 days pre-procedure) 3, 4
The protocol for resuming anticoagulation after the procedure involves resuming warfarin on the evening of or day after the procedure and resuming LMWH 24-72 hours post-procedure based on bleeding risk, with the goal of continuing LMWH until the INR is ≥ 2.0, as suggested by the American College of Chest Physicians 4

Patients with mechanical heart valves require different protocols for perioperative anticoagulation management, as outlined by the American Heart Association 5
The use of a perioperative anticoagulation calendar is recommended to minimize errors in anticoagulation management, according to the American College of Chest Physicians 4
For low bleeding risk procedures, such as dental, dermatologic, or ophthalmologic procedures, consideration should be given to continuing warfarin without interruption, or reducing the warfarin dose 4-5 days before the procedure to allow the INR to fall to 1.3-1.5, to minimize the risk of bleeding complications 6, 1, 7

Unnecessary bridging in low-risk patients increases bleeding risk without reducing thromboembolism, highlighting the importance of careful patient selection for bridging therapy 3
Restarting LMWH too soon after major surgery (within 24 hours) significantly increases bleeding risk, and therefore should be avoided whenever possible 8
Failure to adjust bridging protocols based on procedural bleeding risk can lead to increased bleeding complications, and therefore should be avoided whenever possible 8
Resuming full-dose anticoagulation too soon after procedures with high bleeding risk can lead to increased bleeding complications, and therefore should be avoided whenever possible 8
The FDA specifically warns against using Lovenox for thromboprophylaxis in patients with prosthetic heart valves, highlighting the importance of careful patient selection for bridging therapy 7

The BRIDGE trial demonstrated no difference in arterial thromboembolism between bridging and no-bridging groups (0.3% vs 0.4%), but significantly higher major bleeding in the bridging group (3.2% vs 1.3%), as reported by the American Heart Association, American College of Cardiology, and Heart Rhythm Society 3, 4
The trial concluded that forgoing bridging was non-inferior for preventing thromboembolism and superior for reducing bleeding risk, according to the American Heart Association, American College of Cardiology, and Heart Rhythm Society 3